menu
    • menu
    [{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Erlotinib","moa":"Pan-kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Erlotinib","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Sybleu","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"AQ4","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sybleu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sybleu \/ Oncology Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Sybleu \/ Oncology Pharma"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Erlotinib","moa":"HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Erlotinib

    Menu

    Erlotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Heat Biologics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viagenpumatucel-L,Erlotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

                            Details : New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular products.

                            Brand Name : HS-110

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 25, 2022

                            Lead Product(s) : Viagenpumatucel-L,Erlotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sybleu

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Sybleu

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erlotinib,TNF-alpha derivative

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Oncology Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Oncology Pharma Signs Licensing Deal with Sybleu to market a Chemotherapeutic Agent in Combination with a Bioa...

                            Details : The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand.

                            Brand Name : AQ4

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 26, 2021

                            Lead Product(s) : Erlotinib,TNF-alpha derivative

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Oncology Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genprex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Genprex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quaratusugene ozeplasmid,Erlotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate

                            Details : United States Adopted Names (USAN) Council has approved the non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex™ immunogene therapy, the Company’s lead drug candidate for non-small cell lung cancer (NSCLC).

                            Brand Name : GPX-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 25, 2020

                            Lead Product(s) : Quaratusugene ozeplasmid,Erlotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Genprex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Genprex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tumor Suppressor Candidate 2 gene,Osimertinib Mesylate,Erlotinib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genprex to Focus Its Clinical Efforts on Oncoprex with Osimertinib

                            Details : The company’s current Phase I/II clinical trial utilizes the combination of the EGFR inhibitor erlotinib and Oncoprex against NSCLC.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 05, 2020

                            Lead Product(s) : Tumor Suppressor Candidate 2 gene,Osimertinib Mesylate,Erlotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth